Due to the rigor of the clinical development program of adalimumab for the indication of AS, the population of subjects with active AS that could enroll in previous phase 3 studies was limited. Therefore, it is necessary to further evaluate the use of adalimumab in a setting that mimics day-to-day clinical practice to obtain further safety and efficacy data by allowing subjects meeting the characteristics noted below to enter this study:||Subjects who failed another TNF inhibitor (etanercept, infliximab)|Subjects with advanced spinal ankylosis|Subjects with AS associated disorders (i.e., uveitis, IBD, and psoriasis)